CNS & Neurological Disorders - Drug Targets
Title:Meet Our Editorial Board Member
Volume: 18 Issue: 5
Author(s): Cristoforo Comi
Affiliation:
Export Options
About this article
Cite this article as:
Comi Cristoforo , Meet Our Editorial Board Member, CNS & Neurological Disorders - Drug Targets 2019; 18 (5) . https://dx.doi.org/10.2174/187152731805190620141022
DOI https://dx.doi.org/10.2174/187152731805190620141022 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
37
1
1
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Computer-aided Drug Design Applied to Parkinson Targets
Current Neuropharmacology Recent Advances in Cannabis sativa Research: Biosynthetic Studies and Its Potential in Biotechnology
Current Pharmaceutical Biotechnology Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer
CNS & Neurological Disorders - Drug Targets Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Xanthine Derivatives as Agents Affecting Non-dopaminergic Neuroprotection in Parkinson’s Disease
Current Medicinal Chemistry Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Therapeutic Potential, Synthesis, Patent Evaluation and SAR Studies of Thieno[3,2-d]pyrimidine Derivatives: Recent Updates
Current Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science Drugs Treatment of Pain in Multiple Sclerosis
Current Clinical Pharmacology Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics